Fas ligand (FasL) is a type II integral membrane protein homologous with tumor necrosis factor (TNF) . Recent studies indicate that TNF is processed to yield the soluble cytokine by metalloproteinases at the cell surface of activated macrophages and T cells . In the present study, we investigated whether FasL is also released by metalloproteinases . Treatment with hydroxamic acid inhibitors of matrix metalloproteinases specifically led to accumulation of membrane-type FasL 
Summary
Fas ligand (FasL) is a type II integral membrane protein homologous with tumor necrosis factor (TNF) . Recent studies indicate that TNF is processed to yield the soluble cytokine by metalloproteinases at the cell surface of activated macrophages and T cells . In the present study, we investigated whether FasL is also released by metalloproteinases . Treatment with hydroxamic acid inhibitors of matrix metalloproteinases specifically led to accumulation of membrane-type FasL as (APO-1, CD95) is a type I integral membrane protein initially identified by mAbs that induce apoptotic cell death upon binding to certain tumor cells (1, 2) . Molecular cloning of Fas revealed that it belongs to the TNF receptor family and transducer a cell death signal (3) . Fas is expressed on activated lymphocytes and in various tissues, including the liver, lung, intestine, and skin (4, 5) . It has been reported that administration of an agonistic anti-Fas mAb rapidly killed mice by severely damaging the liver (6) .
Recent molecular cloning of Fas ligand (FasL)l revealed that it is a type II integral membrane protein homologous with TNF (7) . FasL is expressed on activated T and NK cells, and mediates Fas+ target cell lysis by these effector cells (8) (9) (10) . The Fas/FasL system also been also implicated in the pathogenesis of autoimmune diseases, fulminant hepatitis, GVHD, and AIDS (11) (12) (13) . TNF-a, a prototype cytokine of the TNF family, has been well known to be released as the 17-kD secretory form from the 26-kD membrane form (14) . Recent studies indicated that this processing is performed by some matrix metalloproteinases (MMPs) (15) (16) (17) . It has also been recently reported that human FasL was released as a 26-kD soluble form from COS cells transfected with human FasL cDNA and activated human T cells (18) . In this context, we demonstrate here that human FasL is also released by 'Abbreviations used in this paper: c1G, control Ig ; FasL, Fas ligand; rnFasL, membrane FasL ; FFasL, soluble FasL; MMP, matrix metalloproteinase ; P+l, PMA plus ionomycin; RT, reverse transcription .
MMPs such as TNF-ot, as estimated by specific blocking by MMP inhibitors. Physiological and clinical relevance of this finding is discussed .
Materials and Methods
Cells . Mouse T lymphoma cell lines (L5178Y and WR19L) and human Fas cDNA transfectant (hFas/WR19L) (3) were kindly provided by Dr. S . Yonehara (Kyoto University, Kyoto, Japan) and cultured in RPMI-1640 medium containing 10% FCS, 100 N , g/ml each streptomycin and penicillin, and 2 mM glutamine (culture medium) . A human CD4 + T cell clone (4HM1) of Thl type was provided by Dr . M . Azuma (Juntendo University, Tokyo) and maintained in the culture medium supplemented with 50 U/ml of rIL-2 .
Reagents. The following hydroxamic acid-based metalloproteinase inhibitors were synthesized by Kanebo Ltd . (Osaka, Japan) : (20) . A nonhydroxamate derivative of KB8301, (4-hydroxy-2R-isobutyl-3S-methylsuccinyl)-L-3-(5,6,7,8-tetrahydro-1-naphthyl)alanine-Nmethylamide (KB8845), was also synthesized as a negative control . These compounds are available upon request. Other protease inhibitors, including aprotinin, leupeptin, pepstatin, E64, Bestatin, captopril, and phosphoramidon, were purchased from Sigma Chemical Co . (St . Louis, MO) . All these protease inhibitors were dissolved in DMSO at 10 mM as stock solutions . PMA and ionomycin were also purchased from Sigma . OKT-3 mAb was prepared from the hybridoma obtained from the American Type Culture Collection (Rockville, MD) . An anti-Fas mAb (clone CH-11) was purchased from MBL (Nagoya, Japan) . Preparation of the soluble Fas-Ig fusion protein has been described previously (8) .
Generation of Human FasL Transfectants. Human Fast cDNA was prepared by reverse transcription (RT)-PCR from total RNA of activated 4HM1 by using an oligonucleotide corresponding to the first six codons as the 5' primer and to the last six codons as the 3' primer, according to the published sequence (21) . The 5' and 3' primers were tagged with a Xhol or a Nod site, respectively. After XhoI and Nod digestion, the PCR product of 850 by was subcloned into pBluescriptIl SK+ (Stratagene, La Jolla, CA) and the nucleotide sequence was confirmed by sequencing . The 850-bp cDNA was then transferred into the Xhol and Nod sites of the CDM8 or BCMGSneo expression vector (22) , kindly provided by B . Seed (Massachusetts General Hospital, Boston, MA) and H . Karasuyama (Tokyo Metropolitan Institute of Medical Science, Tokyo), respectively . Transient expression of human FasL cDNA (hFasL/CDM8) in COS cells was performed as described previously (8) . Culture supernatant containing soluble FasL (sFasL) was collected after 4 d . For generating stable transfectants, hFasL/BCMGSneo was transferred into L5178Y cells by electroporation (290V ; 960p,F), using a gene pulser (Bio-Rad, Hercules, CA) . After selection with 0 .4 mg/ml G418 and cloning by limiting dilution, a transfectant (hFasL/L5178Y) expressing a high level of hFasL mRNA was selected by Northern hybridization .
Generation ofAnti-human FasL MAbs . 4-wk old female MRL 1pr/ 1pr mice (Clear Japan, Tokyo) were immunized by intraperitoneal injection of hFasL/L5178Y (10' cells) several times at 10-d intervals . 3 d after final immunization, the splenocytes were fused with P3U1 mouse myeloma cells, as described previously (23) . After HAT selection, the antibodies that neutralize Cytotoxic activity of sFasL in the hFasL/L5178Y supernatant against hFas/ WR19L were screened. Three mAbs (NOK-1, NOK-2, and NOK-3) were identified by their strong inhibitory effects and cloned by limiting dilution . NOK-1 (mouse IgG1,ic) and NOK-2 (mouse IgG2a,ic) were purified from ascites by protein G affinity chromatography . NOK-3 (mouse IgM,ic) was purified by ammonium sulfate precipitation and gel filtration .
Cytotoxic Assay . Cytotoxic activity of sFasL in the culture supernatants was tested against the human Fas transfectant by the alamar Blue method, according to the manufacturer's instructions (Alamar Biosciences, Inc ., Sacramento, CA) . Briefly, hFas/ WR19L or WR19L cells (10 4) were cultured with serially diluted hFasL/COS or hFasL/L5178Y supernatant in a total volume of 100 l .tl. After 16 h, 10 p.,l of alamar Blue was added and further incubated for 4 h . Fluorescence of the reduced alamar Blue was measured on a Fuoroskan (Titertek Fluoroskan II ; Labosystems Japan, Tokyo) at 590 nm by excitation at 544 nm .
Immunofluorescence. L5178Y or hFasL/L5178Y cells (106/ml) were cultured with or without various protease inhibitors (10 N,M, unless otherwise indicated) for 24-48 h . 4HM1 cells (106 / ml) were stimulated with ionomycin (500 ng/ml) and PMA (10 ng/ml) in the presence or absence of 10 p,M BB94 for 2-6 h . These cells (106) were incubated with 1 jig of biotinylated NOK-1 for 1 h at 4°C, followed by PE-labeled avidin (PharMingen, San Diego, CA) . After washing with PBS, the cells were analyzed on a FACScan (Becton Dickinson & Co ., San Jose, CA), and data were processed by using the CELLQuest program .
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FasL Processing by Metalloproteinase ELISA for sFasL, TNF-a, and IFN-y. hFasL/L5178Y cells (106/ ml) were cultured with or without various protease inhibitors for 24 h . sFasL in the supernatant was quantitated by sandwich ELISA using NOK-1 and NOK-3 . Briefly, Immulon 2 plates (Dynatech Laboratories Inc ., Chantilly, VA) were incubated overnight with NOK-3 (10 jig/ml) . After washing with 0 .05% Tween/PBS, the wells were blocked by skimmed milk solution (Block Ace ; Snow Brand Milk Co ., Sapporo, Japan) for 2 h at 37°C, 50 N.1 of the sample were added and incubated for 1 h at room temperature, biotinylated NOK-1 (5 jig/ml) was added and incubated for 1 h at room temperature, and 50 wl of ABC solution (Vectastain ABC kit ; Vector Laboratories Inc ., Burlingame, CA) was added and incubated for 30 min at room temperature . The plates were developed with 100~d of I mg/ml orthophenylenediamine in 50 mM citrate-phosphate buffer (pH 5 .0) containing 0 .03% H,O,, and stopped with 100 [,1 of 2N H2SO4-OD at 490 nm was measured on an automated ELISA reader. Serial dilutions of purified sFasL, which was affinity purified from the hFasL/L5178Y supernatant on a NOK-1 column, was used as the standard . Detection limit of this assay was -0 .2 ng/ml . 4HM1 cells (106/ml) were stimulated with immobilized OKT-3 (10 N,g/ml) in the presence or absence of various protease inhibitors for 24 h . sFasL in the supernatant was measured as described above . TNF-a and IFN-'Y in the supernatants were evaluated with commercial ELISA (R & D Systems, Minneapolis, MN) according to the manufacturer's instruction .
Immunoprecipitation . To identify the cellular FasL, hFasL/L5178Y cells (106 /nil) were cultured with 100 1LCi/ml Of [35S] Cys/Met (TransLabel; ICN Biomedical Inc ., Costa Mesa, CA) in the presence of 10 1LM BB94 at 37°C for 16 h . After chasing in fresh culture medium with 10 RM BB94 at 37°C for 4 h, the cells were extracted with a lysis buffer (0 .5% Triton X-100, 20 mM Tris-HCI, pH 7 .6, 150 mM NaCl, 10 ILM PMSF, and 50 N, g/ml trypsin inhibitor) . To identify the sFasL, hFasL/L5178Y cells were cultured with 100 lLCi/ml of [35S] Cys/Met in the absence of BB94 at 37°C for 24 h, and the supernatant was collected . After preclearing with normal mouse control Ig (clg)-coupled Sepharose, the lysate and supernatant were immunoprecipitated with NOK-1-coupled Sepharose for 1 h at 4°C . After washing with the lysis buffer, the bound materials were eluted and subjected to SDS-PAGE under nonreducing or reducing (5% 2-ME) conditions . For fluorography, gels were incubated with Amplify (Amersham Japan, Tokyo) for 30 min, dried, and exposed to x-ray film (XAR-5 ; Eastman Kodak, Rochester, NY) at -80°C for 1 d .
For pulse-chase analysis, 4HM1 cells (106 /ml) were labeled with 100 p,Ci/ml of [35 S] Cys/Met in the presence of ionomycin plus PMA at 37°C for 1 h, then chased in the culture medium with or without 10 N,M BB94 for 1-6 h . Supernatants and cell lysates were prepared from the same culture and immunoprecipitated with NOK-1-Sepharose . The eluates were subjected to SDS-PAGE and fluorography as described above . Intensities of the p40 and p27 bands were measured on an image analyzer (Fujix BAS 2000; Fuji Photo Film Co . Ltd ., Tokyo) .
To identify the membrane Fast (mFasL), hFasL/L5178Y cells were surface-labeled with sulfo-N-hydroxysuccinimide-biotin, as described previously (23) . The cells were extracted with the lysis buffer, precleared with clg-Sepharose, and immunoprecipitated with NOK-1-Sepharose . After washing with the lysis buffer, the eluates were subjected to SDS-PAGE and electroblotted onto nitrocellulose membrane filters . The blots were subsequently incubated with Vectastain ABC solution, developed with ECL Western blotting detection reagents (Amersham Japan), and exposed to x-ray films for a few minutes .
Results and Discussion
Human Fast, cDNA Transfectants Release Functional Fast,. To characterize the functional properties of human Fast,, we generated a stable transfectant. Human Fast, cDNA was prepared by RT-PCR from total RNA of activated human T cell clone (4HM1) and introduced into a mouse T lymphoma cell line (L5178Y) that does not express Fas (8) exhibited specific cytotoxicity against hFas/WR19L in a dose-dependent manner (Fig. 1 A) . As measured by the sandwich ELISA described below, the hFasL/L5178Y and hFasL/COS supernatants contained sFasL at 13.5 ng/ml and 8.7 ng/ml, respectively. When dilution ofthe supernatant was converted to the concentration of sFasL (Fig. 1 B) , sFasL derived from the L5178Y and COS transfectants exhibited almost comparable specific activity (ED50 = 3.4 ng/ ml and 2 .9 ng/ml, respectively) . These were also comparable to the specific activity of natural sFasL derived from anti-CD3-stimulated 4HM1 (data not shown) . In comparison, the most widely used agonistic anti-Fas mAb (CH-11) exhibited 2.5-fold lower specific activity (EDso = 8.1 ng/ ml) than did sFasL . These results indicate that sFasL derived from various cellular backgrounds exhibits a comparable and potent specific activity, suggesting that they might undergo a similar processing.
MMP Inhibitors Induce Accumulation of Fast, on Cell Surfaces. To characterize human Fast, further, we generated several mAbs. To avoid possible lethality of Fast,, Fas-deficient MRL lpr/lpr mice (6) were immunized with hFasL/ L5178Y and the immune splenocytes were fused with P3U1 myeloma. After screening the ability to neutralize the Fast, activity in the hFasL/L5178Y supernatant, we established three mAbs, termed NOK-1 (IgG1,ic), NOK-2 (IgG2a,ic), and NOK-3 (IgM,ic) . These mAbs neutralized human Fast, activity 20-50-fold more efficiently than soluble Fas-Ig fusion protein (Fig. 2) . As represented in Fig. 3 A, NOK-1, as well as NOK-2 and NOK-3 (not shown), reacted with hFasL/L5178Y but not with L5178Y, as estimated by surface immunofluorescence and flow cytometry.
Recently, it has been demonstrated that the release of TNF-a, which is homologous with Fast,, from activated T cells and monocytes is mediated by metalloproteinase(s) (15) (16) (17) 24) and that treatment with MMP inhibitors led to surface accumulation of TNF-ct on these cells (17, 24) . In response to these stimulations, as estimated by Northern hybridization and specific cytotoxicity against hFas/ WR19L (data not shown) . Consistently, NOK-1 did not react with unstimulated 4HM1 but did react with P+I-stimulated 4HM1 (Fig. 3 B) . In the presence of BB94, the level of surface FasL was progressively increased . KB8301 and KB8112 but neither KB8845 nor other protease inhibitors gave a similar result (data not shown) . Induction of FasL mP NA was not affected by BB94, as estimated by Northern hybridization (not shown) . These results suggested that the MMP inhibitors induced the surface accumulation of FasL on the transfectants and activated T cells by inhibiting the processing by some MMP.
MMP Inhibitors Block sFasL Release . By utilizing NOK-1 and NOK-3, we established a sandwich ELISA system for sFasL (see Materials and Methods), which enabled us to es-178 1 Kayagaki et al . timate sFasL release quantitatively . We then examined the effect of MMP inhibitors on sFasL release . The hydroxamic acid-based MMP inhibitors (BB94, KB8301, and KB8112) but not the non-hydroxamic acid control (KB8845) inhibited the sFasL release from hFasL/L5178Y in a dose-dependent manner (Fig. 4 A) . The other protease inhibitors tested were not effective (not shown) . In Fig . 4 B, we also tested the effect of BB94 and KB8112 on the release of sFasL, TNF-a, and IFN-y from OKT-3-stimulated 4HM1 . These MMP inhibitors inhibited the release of sFasL and TNF-et comparably but not the release of IFN-y. This result not only rules out an inhibitory effect of these MMP inhibitors on T cell activation but also suggests a close correlation between the TNF processing enzyme and the FasL processing enzyme.
Biochemical Characterization of FasL Processing . The processing of FasL was biochemically characterized by immunoprecipitation and SDS-PAGE analysis . To identify the mFasL, hFasL/L5178Y cells were metabolically labeled with [3'S] Cys/Met in the presence ofBB94, which leads to accumulation ofmFasL . As represented in Fig. 5 A, NOK-1 specifically precipitated the 40-kD band (p40) under reducing and nonreducing conditions from the BB94-treated hFasL/L5178Y but not from L5178Y (not shown) . This result appears to represent the mFasL as described in COS cell transfectant (18) . In some cases, an additional 80-kD band (Fig. 5 A) and a faint 120-kD band were also detected under nonreducing conditions, which might represent a dimer and trimer, respectively, as described for sFasL (18) . On the other hand, sFasL was immunoprecipitated by NOK-1 from the culture supernatant of 35S-Cys/Metlabeled hFasL/L5178Y as a 27-kD band (p27) under nonreducing and reducing conditions (Fig. 5 A) . Although oligomers o£ sFasL were barely detected in our SDS-PAGE analysis, FasL activity in the hFasL/L5178Y supernatant was eluted around Mr of-80 kD in gel filtration (data not shown), suggesting that sFasL is present as a trimer, as demonstrated in the supernatant of COS cell transfectant (18) .
NOK-1 immunoprecipitates from the surface biotinylated hFasL/L5178Y lysate typically exhibited two bands of 40 and 27 kD, which apparently represent mFasL and sFasL, respectively (Fig. 4 B) . The 27-kD band (p27) was also detected occasionally in the lysate of [3IS]Cys/Met-labeled hFasL/L5178Y cells (not shown) . This suggests that some sFasL is anchored on the cell surface as a part of partially processed mFasL trimer like lymphotoxin-et anchored by lymphotoxin-(3 (25) . As represented in Fig. 5 B, an additional 60-kD band, whose identity is unknown, was also detected occasionally.
We also examined the kinetics of the processing in activated T cells by pulse-chase analysis . PMA/ionomycinactivated 4HM1 cells were pulse-labeled with [35S]Cys/ Met for 1 h and then chased in the culture medium with or without BB94 (Fig. 5 C) . In the absence of BB94, mFasL (p40) in the cell lysate was rapidly lost and, concomitantly, sFasL (p27) was accumulated in the supernatant . In the presence of BB94, the loss of p40 in the lysate and the accumulation of p27 in the supernatant were greatly reduced, of p40 in the lysate or p27 in the supernatant when p40 in the 131394-treated cell lysate at 1 h and p27 100%, respectively. demonstrating that BB94 is acting at the cell surface to inhibit FasL processing . Comparison of the band intensities revealed that 75% of p40 was processed to p27 and 57% was released into the supernatant within the first 1 h, indicating a high efficiency of FasL processing on the activated T cell surface .
This study indicated that human FasL is released from the T cell surface via processing by some MMP, as was the case with TNF-a . A closely correlated sensitivity to various protease inhibitors raises a possibility that these two type II integral membrane proteins may be processed by the same metalloproteinase . In our preliminary study, activated T cells express a limited repertoire of known MMPs, as reported by others (26) . Identification of a candidate enzyme Receivedfor publication 5July 1995 and in revisedform 7 August 1995 .
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FasL Processing by Metalloproteinase is now in progress . Recent studies demonstrated that administration of an MMP inhibitor that blocked the TNF processing protected mice from lethal endotoxin shock, which is mainly mediated by macrophage-derived TNF (15) . We also observed that KB8301 and BB94 have a similar effect (unpublished data) . On the other hand, activated T cell-derived FasL has been implicated in the pathogenesis of virus hepatitis and GVHD (12) , in which TNF has been also implicated (27) . In our preliminary study, some patients suffering from fulminant hepatitis or GVHD exhibited a high serum sFasL level, as estimated by the ELISA (unpublished data) . Therefore, the MMP inhibitors that block both sFasL and TNF release would be clinically useful for the treatment of these diseases .
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